Arcosa, Inc.

Executive Summary

HOLD, High conviction. ACA is subject to a pending acquisition by CRH at ~$145.71/share in cash, and that deal now overrides the normal valuation debate. The quant price target is $126.02, -13.1% vs current $144.97, with Low confidence, while the company carries a Quality score of 53/100 and Risk score of 42/100 (Moderate). The practical conclusion is simple: the business was improving, but the stock is now a spread product with only about $0.74/share of remaining upside and meaningful downside if the transaction breaks.

ACA has rallied sharply into the offer, up 16.31% in 1M, 31.67% in 3M, and sitting -1.3% from both its 52-week high of $146.92 and 5-year high of $146.92. That price action is exactly what a near-cash takeout should look like. At this level, the decision is not whether Arcosa is a good business. The decision is whether a roughly 0.5% gross spread compensates investors for closing risk, timing risk, and the downside back to standalone valuation if anything slips.

Investment Thesis

ACA is no longer a clean infrastructure growth thesis for public shareholders. It is a merger-arbitrage position with capped upside. The agreed $8.5B cash acquisition by CRH sets the value anchor, and the stock has already moved to within cents on the dollar of that consideration.

That leaves a poor asymmetry for new money. If the deal closes on time, the return from $144.97 to ~$145.71 is trivial. If the deal breaks for regulatory, financing, or process reasons, investors are immediately pushed back into standalone valuation, where the quant framework is explicit: $126.02 fair value on an earnings_growth_blend, with component methods ranging from P/E Multiple $138.92 to DCF $74.87. When the upside is less than 1% and the downside is plausibly double digits, patience is the right call.

Financial Strength

The underlying business entered the sale process in better shape than the trailing FY2025 numbers suggest. FY2025 revenue was $2.9B, up 6.8% YoY, but EPS fell to $4.25, down 47.4% YoY, operating margin slipped to 7.3% from 7.7%, and net margin was just 3.0%. Those numbers help explain why the standalone valuation case was never straightforward despite decent revenue growth.

More recent operating data is better. In Q1 2026, ACA generated $0.10B of EBITDA on $0.57B of revenue, a 17.9% margin, up 30 bps from prior-year Q1 even though it was down from 19.1% in Q4. Management also highlighted that free cash flow from continuing operations improved to $21M from negative $49M last year.

The balance sheet also improved after portfolio reshaping. The company completed a $450M barge divestiture on April 1, and pro forma leverage moved down to 1.9x net debt/EBITDA, below target. On the reported balance sheet, debt/equity was 0.58, debt/EBITDA 2.65, current ratio 2.31, and total debt $1.5B. None of that points to financial stress, but the FY2025 FCF of $0.0B is a reminder that this is still a capex-heavy business.

Competitive Position

ACA's strongest position is in utility structures, and that was becoming more valuable before the CRH bid. Utility structures backlog reached a record $558M, up 28% from the start of the year. Management said Engineered Structures exceeded expectations, with utility structures delivering >15% revenue growth and 300 bps segment margin expansion.

Capacity additions support that advantage. The Illinois wind tower plant conversion is ahead of schedule, with large utility poles expected by the end of Q2. The New Mexico galvanizing facility completed its first dip in April, with commercial operations expected in Q2. Those are real, tangible operating steps that strengthen ACA's position in grid-related infrastructure.

The moat is still narrow to moderate rather than exceptional. This is a physical infrastructure products company, not a software platform. AI helps at the margin through plant efficiency, logistics, maintenance, and bidding, but it does not fundamentally change ACA's pricing power. The more important secular force is utility grid investment and infrastructure spend. That remains favorable, but it now matters more to CRH's strategic rationale than to ACA's standalone public equity upside.

Management & Guidance

Management execution improved markedly after one weak quarter in early 2025. The earnings track record shows 7 beats in the last 8 reports, including 0.51 vs 0.13 on 2026-04-30, a +292.3% surprise, 1.15 vs 0.95 on 2026-02-26, and 1.56 vs 1.33 on 2025-10-30. The only miss in the series was 0.46 vs 0.79 on 2025-02-27, a -41.8% miss.

That improving cadence gives management more credibility than the FY2025 headline EPS decline alone would imply. On the Q1 2026 call, CEO Antonio Carrillo said: "At the midpoint of our guidance range, we expect adjusted EBITDA of $565 million, up $22.5 million from our previous guidance range, representing 11% growth year-over-year." He also said: "At the midpoint of our guidance range, we anticipate revenues of $2.65 billion, up 6% year-over-year and adjusted EBITDA of $565 million, up 11% year-over-year. We expect margin to expand to a record 21.3%."

CFO Gail Peck added: "Segment margin increased to a record 21.1%, up 300 basis points year-over-year due to strong utility structures performance." She also said: "So a long-winded way of saying our margin expectation for this segment has increased, and we would see an annual margin in the 20% range sustainable for the year." On demand visibility, Carrillo said: "We're raising the guide for 2 reasons. Performance has been very good. But we have the backlog already in place to support our guidance."

That said, not every piece of the portfolio is firing. Residential demand remains flat to slightly down in aggregates for 2026, with recovery pushed to 2027. Q2 also absorbs peak start-up costs from Clinton and the galvanizer, and elevated diesel prices would create an unabated 4%-5% headwind to aggregates cash unit profitability.

Bull Case

First, the deal itself provides near-certain value if it closes. ~$145.71/share in cash is tangible and does not depend on further multiple expansion.

Second, ACA was improving operationally into the transaction. FY26 guidance calls for $2.65B revenue, $565M adjusted EBITDA, and a 21.3% margin, all stronger than the FY2025 profile.

Third, utility structures is a real growth engine. Record $558M backlog, >15% revenue growth, and 300 bps margin expansion suggest a business with better earnings power than the trailing results show.

Fourth, management's recent execution was strong. 7 beats in 8 quarters and a raised outlook support the view that the standalone business likely had more runway.

Bear Case

The main bear point is the trivial spread. A new investor is risking a lot to make very little.

The second issue is break value. The quant target is $126.02, and the valuation methods are scattered: P/E Multiple $138.92, PEG $46.31, P/S Multiple $182.61, Quality-adjusted $148.45, DCF $74.87. That dispersion reflects genuine uncertainty about standalone fair value.

Third, peer valuation is not especially clean. The target leans on 8 peers with an average P/E of 34.0, but peer dispersion is wide at 7.5x, and some cited comps are extreme, including NPO at 162.86x and POWL at 47.83x. That lowers confidence in any claim that ACA is obviously cheap on public multiples.

Fourth, profitability quality remains only average. The quality sub-scores show Profitability 38, Cash Flow Quality 34, and Financial Health 45, which fits a business that has improved but is not elite.

Valuation & Price Target

The stock should not be valued primarily on standalone DCF or peer multiples while the CRH transaction is pending. The market is correctly treating ACA as a deal spread.

For reference, the quant price target is $126.02, implying -13.1% versus the current $144.97, with Low confidence and basis earnings_growth_blend. Method outputs are P/E Multiple $138.92, PEG (growth-adjusted) $46.31, P/S Multiple $182.61, Quality-adjusted $148.45, and DCF $74.87. Those numbers are useful mainly as break-price context, not as a live target while the cash offer stands.

Analyst consensus is Strong Buy, 2 buy / 0 hold / 0 sell, but that is a LOW signal and not especially relevant post-announcement. The more important cross-check is that quant says HOLD, and that remains the right practical stance, even if the reason is now merger math rather than pure fundamentals.

Risk Assessment

The biggest risk is binary: deal completion. Small shareholder-law-firm investigations are common after public M&A and do not change the base case by themselves, but they add noise around process and price adequacy. If there is any regulatory delay, unexpected condition, or renegotiation attempt, the stock has little buffer given how close it trades to the offer.

Standalone business risk is secondary but real. Aggregates residential demand is soft, diesel can pressure cash profitability by 4%-5%, and startup costs weigh on Q2. Those issues matter far more if the deal fails than if it closes.

The Bottom Line

ACA is a HOLD. The operating story had turned better, with raised FY26 guidance, a record utility backlog, improving free cash flow from continuing operations, and lower leverage. But those positives are now mostly captured by the CRH cash offer at ~$145.71/share.

At $144.97, public shareholders are being offered a tiny spread and a lot of asymmetrical downside if the transaction slips or breaks. Holding existing shares for completion is reasonable for merger-arb accounts that understand the risk. Chasing the stock here is not.